|
Abstract: Objective To observe effect of the degrees of fatty liver disease in rat with type 2 diabetes mellitus and nonalcoholic fatty liver disease was inhibited by Gypenosides and Ginkgo Biloba Extract Mixture. Methods Total of 40 SPF male SD rats, body mass 220-250 g, were randomly divided into blank control group, model group with type two diabetes mellitus and nonalcoholic fatty liver disease. After eight weeks the NAFLD model in rats was maked, model group were divided into three groups: treatment group were perfused with 500 mg/(kg·d) GPS and 0.1g/(kg·d) ginkgo biloba extract mixture, control group were perfused with 500 mg/(kg·d) GPS, model group were perfused with the same volume of water, and high fat diet at the same time, the experimental period was six weeks. The experimental period was 14 weeks. Blood sugar, triglycerides, total cholesterol (TC), ALT, AST in the plasma in rat was test. It was tested that triglycerides in the liver tissue. The Liver tissue was detected by pathology. Results BS levels in plasma: blank control group (5.50 ± 0.51) mmol/L, model group (18.76 ± 4.20) mmol/L, treatment group (10.78 ± 3.389) mmol/L, control group (14.62 ± 3.32) mmol/L, treatment group and control group was lower than model group, there was a significant difference (P ＜ 0.01), treatment group was lower than control group, there was a significant difference (P ＜ 0.05). TG levels in plasma: blank control group (0.81 ± 0.11) mmol/L, model group (1.29 ± 0.14) mmol/L, treatment group (0.90 ± 0.09) mmol/L, control group (1.09 ± 0.10) mmol/L, treatment group and control group was lower than model group, there was a significant difference (P ＜ 0.01), treatment group was lower than and control group, there was a significant difference (P ＜ 0.05). TC levels in plasma: blank control group (1.39 ± 0.13) mmol/L, model group (3.69 ± 0.27) mmol/L, treatment group (2.59 ± 0.19) mmol/L, control group (3.11 ± 0.18) mmol/L, treatment group and control group was lower than model group, there was a significant difference (P ＜ 0.05), treatment group was lower than control group (P ＜ 0.05). ALT levels in plasma: blank control group (35.12 ± 3.34) U/L, model group (60.68 ± 5.12) U/L, treatment group (42.13 ± 4.99) U/L, control group (50.12 ± 4.68) U/L, treatment group and control group was lower than model group, there was a significant difference (P ＜ 0.05), treatment group was lower than control group (P ＜ 0.05). AST levels in plasma: blank control group (81.15 ± 7.14) U/L, model group (168.12 ± 10.49) U/L, treatment group (112.23 ± 10.12) U/L, control group (139.12 ± 11.68) U/L, treatment group and control group was lower than model group (P ＜ 0.01), treatment group was lower than control group (P ＜ 0.01). TG levels in liver tisue: blank control group (30.26 ± 2.48) mg/g, model group (228.46 ± 8.48) mg/g, treatment group (153.12 ± 9.98) mg/g, control group (196.24 ± 9.78) mg/g, treatment group and control group was lower than model group, there was a significant difference (P ＜ 0.05), treatment group was lower than control group (P ＜ 0.05). Liver pathology: blank control group was normal liver tissues. Model group was severe fatty liver disease. Treatment group and control group was moderate to severe fatty liver disease, and treatment group was lighter than control group. Conclusions The degree of T2DM and nonalcoholic fatty liver disease in rats was inhibited by gypenosides and ginkgo biloba extract mixture, through blood sugar and lipid metabolism adjusted, and reduce the liver tissue TG deposition, protecting liver cells.
|